A ''dysfunctional tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4. It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5
* VAT and and shipping costs not included. Errors and price changes excepted
